Topics

European Commission Approves Risankizumab for Plaque Psoriasis

13:16 EDT 1 May 2019 | Medscape

In clinical studies, patients with moderate to severe plaque psoriasis saw significantly higher rates of skin clearance with risankizumab compared to current standards of care.
International Approvals

Original Article: European Commission Approves Risankizumab for Plaque Psoriasis

NEXT ARTICLE

More From BioPortfolio on "European Commission Approves Risankizumab for Plaque Psoriasis"

Quick Search

Relevant Topics

Alzumab (Itolizumab)
Biocon Launches ALZUMAb™ - a ‘First in Class’ Novel Biologic Treatment for Psoriasis Patients in India • ALZUMAb™-World's first novel anti-CD6 antibody developed by Biocon to address a large unmet need for th...

Dermatology
Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...